Valuation: Simulations Plus, Inc.

Market Cap 371M 321M 300M 276M 520M 35.29B 526M 3.52B 1.38B 17.66B 1.39B 1.36B 58.48B P/E 2026 *
43.7x
P/E 2027 * 40.1x
Enterprise Value 371M 321M 300M 276M 520M 35.29B 526M 3.52B 1.38B 17.66B 1.39B 1.36B 58.48B EV / Sales 2026 *
4.53x
EV / Sales 2027 * 4.3x
Free-Float
83.08%
Yield 2026 *
-
Yield 2027 * -
1 day-0.14%
Current month+0.55%
1 month-0.16%
3 months+16.68%
6 months+29.63%
Current year+0.55%
1 week 18.22
Extreme 18.22
18.37
1 month 18.19
Extreme 18.19
18.45
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
52.69
5 years 11.09
Extreme 11.09
67.59
10 years 7.9
Extreme 7.9
90.92
Manager TitleAgeSince
Chief Executive Officer 67 26/06/2018
Director of Finance/CFO 63 01/12/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 17/07/1996
Director/Board Member 58 03/12/2014
Chairman 76 17/12/2024
Date Insider Type Main position Quantity % Market Cap.
6/7/26 Sell

Executive/Senior Manager

-1,000 0.0050%
1/7/26 Sell

Founder

-4,177 0.0207%
15/6/26 Fiscal year

Executive/Senior Manager

3,150 0.0156%
Change 5-day change 1-year change 3-year change Capi.($)
-0.14%0.00%+41.98%-64.41% 371M
+0.06%+2.07%-24.60%+7.82% 34.42B
+4.24%+10.42%-42.54%+156.46% 12.7B
-0.37%-5.44%-24.18%+63.29% 5.43B
-1.15%+7.39% - - 2.35B
+1.82%+11.43% - - 1.83B
+0.31%-10.02%+22.13%-42.93% 1.69B
-1.67%+3.75%-32.87% - 1.06B
+3.28%+6.76%+34.31%+118.10% 873M
-0.27%+9.82%-37.88%-48.82% 849M
Average +0.52%+2.48%-7.96%+27.07% 6.16B
Weighted average by Cap. +0.83%+4.23%-26.18%+45.53%

Financials

2026 *2027 *
Net sales 81.87M 70.91M 66.1M 60.8M 115M 7.78B 116M 777M 305M 3.9B 307M 301M 12.9B 86.26M 74.71M 69.64M 64.05M 121M 8.2B 122M 818M 321M 4.1B 324M 317M 13.59B
Net income 9.53M 8.26M 7.7M 7.08M 13.36M 907M 13.51M 90.45M 35.5M 454M 35.81M 35.02M 1.5B 10.18M 8.82M 8.22M 7.56M 14.27M 968M 14.43M 96.59M 37.91M 484M 38.24M 37.4M 1.6B
Net Debt - -
Logo Simulations Plus, Inc.
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Date Price Change Volume
06/08/26 USD 18.33 -0.11% 85,142
04/08/26 USD 18.35 +0.22% 150,057
03/08/26 USD 18.31 +0.44% 208,917
31/07/26 USD 18.23 -0.38% 377,979
30/07/26 USD 18.30 -0.16% 215,369
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
18.35USD
Average target price
17.25USD
Spread / Average Target
-5.99%

Quarterly revenue - Rate of surprise